EPRX: Eupraxia Pharmaceuticals Inc. Company Value to Net Income

Corporate emblem and logo of Eupraxia Pharmaceuticals Inc. (EPRX)

Eupraxia Pharmaceuticals (EPRX) focuses on developing sustained-release drug delivery systems, which ensures high returns due to the uniqueness of its solutions. The business relies on stable demand for analgesics, which remains independent of economic cycles or inflation. The company's price chart demonstrates a value of -9.00, while production is partially automated, although clinical interaction remains human-led.

EPRX Eupraxia Pharmaceuticals, Inc.: Price to Earnings Ratio in the range 04/06/2024 - 11/16/2026

Comprehensive metric breakdowns and analytics for Eupraxia Pharmaceuticals, Inc. (EPRX)

- market capitalization information:
Comprehensive company analysis:Eupraxia Pharmaceuticals Inc. - EPRX
Flagship merchandise of Eupraxia Pharmaceuticals Inc.

Eupraxia Pharmaceuticals is developing the innovative DiffuSphere technology for the prolonged management of osteoarthritis pain. The P/E ratio determines the market value of a single unit of net profit, reflecting investors' willingness to pay a premium for future business growth. This metric allows for a balance between the risk of overpaying for an asset and the probability of missed opportunities. By analyzing the dynamics of the estimated P/E ratio, one can determine the degree to which shares are overvalued relative to the company's actual earnings.

Key competitors

HLN: Company Value to Net Income|Price to Earnings Ratio KVUE (Kenvue Corp)|VRNA (Verona Pharma Inc.) - Company Value to Net Income|Price to Earnings Ratio Jyong Biotech Limited MENS|Ligand (LGND) - Market Cap to Earnings|AMRX: Price to Earnings Ratio|Perrigo - Market Price to Net Income Ratio|ALVO: P/E Multiple|Liquidia Technologies - Company Value to Net Income|GLPG (Galapagos N.V.) - P/E Multiple|Market Cap to Earnings anipharmaceuticals.com ANIP|Price to Earnings Ratio MannKind (MNKD)|AMPH (Amphastar Pharmaceuticals, Inc.) - Company Value to Net Income|Price to Earnings Ratio Pacira BioSciences, Inc. PCRX|P/E Multiple ARS Corp SPRY|Theravance Biopharma - P/E Multiple|Market Cap to Net Income Ratio Aquestive Therapeutics, Inc. (AQST)|scPharmaceuticals (SCPH) - Price to Earnings Ratio|Price to Earnings Ratio Tectonic Therapeutic, Inc.|TNXP (Tonix Pharmaceuticals Holding) - P/E Multiple|Price to Earnings Multiple SXTC (China SXT Pharmaceuticals)|P/E Multiple BHST|EXOZ - Market Cap to Earnings|P/E Multiple ORMP (oramed.com)|P/E Multiple enterabio.com ENTX|HYFT - Price to Earnings Ratio|Business Payback Period ABVC BioPharma, Inc ABVC|CPIX: P/E Multiple|Quantum BioPharma Ltd - Company Value to Net Income|Price to Earnings Ratio FGEN|Telomir Pharmaceuticals, Inc. - Market Cap to Net Income|P/E Multiple RANI|SNYR (Synergy CHC) - Company Value to Net Income|Price to Earnings Ratio Rallybio RLYB|Lexaria Bioscience (LEXX) - Market Cap to Earnings|PULM - Price to Earnings Ratio|Business Payback Period Pheton Holdings PTHL|APM (Aptorum) - Price to Earnings Ratio|Lyra Therapeutics, Inc. (LYRA) - P/E Multiple|IBO (impactbiomedinc.com) - P/E Multiple|TNFA (TNF Pharmaceuticals) - Market Price to Net Income Ratio|Price to Earnings Ratio cbdmd.com (YCBD)|Business Payback Period PainReform Ltd|P/E Multiple CYTO (Altamira Therapeutics Ltd.)|Lipella Pharmaceuticals (LIPO) - Market Cap to Earnings|OPTN - Price to Earnings Ratio|Pieris Pharmaceuticals - Market Price to Net Income Ratio|PROC (Procaps Group) - Price to Earnings Ratio|PTPI - Business Payback Period|Price to Earnings Ratio Qilian International Holding Group Limited|SLRN: Company Value to Net Income|Price to Earnings Ratio TFFP (TFF Pharma)